Zobrazeno 1 - 4
of 4
pro vyhledávání: '"Allison Berger"'
Autor:
J. Claire Godbersen, Christopher George Danes, Taylor Rowland, Alexey V. Danilov, Cody Paiva, Allison Berger, Olga V. Danilova
Publikováno v:
Oncotarget
// Cody Paiva 1, * , J. Claire Godbersen 2, * , Taylor Rowland 1 , Olga V. Danilova 3 , Christopher Danes 4 , Allison Berger 4 , Alexey V. Danilov 1 1 Knight Cancer Institute, Oregon Health and Science University, Portland, OR, USA 2 Geisel School of
Autor:
Glen J. Weiss, John S. Kauh, Bruce J. Dezube, Jeffrey W. Clark, Roger B. Cohen, Devalingam Mahalingam, James M. Cleary, Hélène M. Faessel, Allison Berger, Michael D. Pickard, George Mulligan, Kristin E. Burke, R. Donald Harvey, Geoffrey I. Shapiro, John Sarantopoulos
Publikováno v:
Clinical Cancer Research. 22:847-857
Purpose: To determine the dose-limiting toxicities (DLTs) and maximum tolerated dose (MTD) of the investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) and to investigate pevonedistat pharmacokinetics and pharmacodyna
Autor:
Mitchell R. Smith, Catherine Diefenbach, Kevin R. Kelly, Andrzej Jakubowiak, Zhaowei Hua, R. Donald Harvey, Sagar Lonial, Daniel Lebovic, Bruce J. Dezube, George Mulligan, Hélène M. Faessel, Owen A. O'Connor, Jatin J. Shah, Stephen Tirrell, Robert Z. Orlowski, Allison Berger
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 22(1)
Purpose: Evaluate the safety, pharmacokinetic profile, pharmacodynamic effects, and antitumor activity of the first-in-class investigational NEDD8-activating enzyme (NAE) inhibitor pevonedistat (TAK-924/MLN4924) in patients with relapsed/refractory l
Autor:
Olga Tayber, Erik Kupperman, Zhi Li, Joseph B. Bolen, Ping Li, Kristen Bano, Jennifer Terkelsen, Allison Berger, Brian G Van Ness, Michael D. Pickard, Matthew D. Silva, Mary Carsillo, Paul Hales, Michael Fitzgerald, Siegfried Janz, Ozlem Subakan, Daniel P. Bradley, Mark Manfredi, Edmund Lee, Vishala T. Neppalli, Bret Bannerman, Jill Donelan, Raymond W. Liu
Publikováno v:
Clinical cancer research : an official journal of the American Association for Cancer Research. 17(23)
Purpose: The clinical success of the first-in-class proteasome inhibitor bortezomib (VELCADE) has validated the proteasome as a therapeutic target for treating human cancers. MLN9708 is an investigational proteasome inhibitor that, compared with bort